tirzepatide fda approval for weight loss when was approved https://investor.lilly.com/news-releases/news-release-details/zepbound- tirzepatide-most-prescribed-weight-management “Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) a label Tirzepatide Unlikely to Exacerbate DR

Note: If you experience severe redness, warmth, or swelling at the injection site that lasts more than 48 hours, contact a healthcare professional immediately

Pharmacological Approaches Anti-spasmodics, including dicyclomine, hyoscyamine, and hyoscine, may reduce abdominal pain by relaxing intestinal smooth muscle, but can worsen constipation and lack strong evidence for IBS-C pain relief [104, 105]

Others benefit from longer-term therapy to support metabolic stability or maintain weight loss

Moreover, studies conducted on animal models have shown that enteroendocrine L-cells increase the secretion of GLP-1 in response to inflammatory cytokines (e.g., interleukin-6 (IL-6) and lipopolysaccharide (LPS) (38)) and ischaemic injury (39)